Phase 2 N=18 Targeting Oxidative Stress in Chronic Beryllium Disease
Chronic Beryllium Disease
Primary: Change in Beryllium Lymphocyte Proliferation Responses (BeLPT) From Baseline to Week 6 — 48.61; 9.33; 22.07; 3.8 Stimulation index
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=120 Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
Herpes Zoster
Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms — 25; 19; 22; 4 Participants
Phase 2 N=1,340 Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older
Influenza
Primary: Number of Subjects Seropositive for Haemagglutination Inhibition (HI) Antibodies Against the A/California Virus Strain — 91; 48; 168; 75 Participants
Phase 2 N=146 BKM120 for Patients With PI3K-activated Tumors
PI3K Pathway Activated Tumors
Primary: Participant Clinical Benefit Response Rate — 15.1 percentage of participants
Phase 2 N=176 Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial
Staphylococcus Aureus
Primary: Assessment of Safety Through Clinical Examinations, Clinical Laboratory Results, Self-reported Diary Reactogenicity Data and Adverse Event Reports — 37; 40; 28; 36 events
Phase 2 N=102 High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma
Multiple Myeloma
Primary: Number of Participants With Pulmonary Toxicity — 32 Participants
Phase 2 N=503 Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)
Coronary Artery Disease (CAD)
Primary: Clinical Events Defined as the Composite of 30-day Death, MI, Repeat Revascularization, Catheter Thrombus, Stroke, Thrombocytopenia, Bailout Use of Glycoprotein IIb/IIIa…
Phase 2 N=410 Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years
Herpes Zoster
Primary: Frequency of gE-specific Cluster of Differentiation 4 (CD4+) T-cells Expressing at Least 2 Different Immunological Activation Markers — 231.82; 570.36; 2172.37; 2582.80…
Phase 2 N=184 Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
Relapsing Remitting Multiple Sclerosis
Primary: Total Number of Adverse Events During Evaluation of Long Term Safety and Tolerability of BAF312A in Extension Study. — 4; 7; 6; 6 events
Phase 2 N=509 Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection
Bacteremia
Primary: Cure Rate — 207; 209 Participants
Phase 2 N=15 IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer
Merkel Cell Carcinoma
Primary: Percentage of Participants Who Experienced At Least 2-Fold Increase in Expression of IL-12 Protein in the Tumor Tissue After Intratumoral (IT) pIL-12 Injections and In…
Phase 2 N=20 Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
Sarcoma
Primary: Number of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 2; 0 participants
Phase 2 N=198 Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma
Asthma
Primary: Change From Baseline in Asthma Control Questionnaire (ACQ-7) Over 12 Weeks — -0.1; -0.2; -0.1; -0.3 Scores on Scale — p=0.1955
Phase 2 N=265 Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
Cirrhosis, Liver
Primary: Mean Change From Baseline in Liver Biopsy Immunohistochemical Marker of Hepatic Stellate Cell (HSC) Activation and Collagen Synthesis at Week 52 — 0.02065; 0.02819…
Phase 2 N=23 Pilot Indocyanine Green Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast Cancer
Breast Cancer
Primary: Agreement of Labeling Between Isosulfan Blue (IS-BLUE) and Indocyanine Green (IC-GREEN) — 8 Participants